A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 4, 1996, Pages 356-362

  Jodrell, Duncan I ^a   Murray, Lilian S ^b   Hawtof, Jeffrey ^c,d   Graham, Martin A ^e,f   Egorin, Merrill J ^c,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f Sanofi Synthelabo Inc   (United Kingdom)

Author keywords

DuP 941; Limited sampling strategy; Pharmacokinetics

Indexed keywords

ANTHRAPYRAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; LOSOXANTRONE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; SAMPLING; TECHNIQUE;

ADULT; AGED; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRAZOLONES; REGRESSION ANALYSIS; SAMPLING STUDIES;

EID: 0030032894     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050397     Document Type: Article

References (28)

1. Brown MB, Engelman L, Jennrich RI (eds) (1990) BMPD statistical software. University of California Press, Berkeley
2. Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA (1992) Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol 31: 37-45
3. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9: 739-756
4. D'Argenio DZ, Schumitsky A (1990) ADAPT II user's guide. Biomedical Simulations Resource, University of Southern California, Los Angeles
5. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL (1988) An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 44: 232-238
6. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokineties. Cancer Res 49: 3129-3133
7. Forrest A, Hawtof J, Egorin MJ (1991) Evaluation of a new program for population PK/PD analysis applied to stimulated phase I data. Clin Pharmacol Ther 49: 153
8. Foster BJ, Newell DR, Graham MA, Gumbrell LA, Jenns KE, Kaye SB, Calvert AH (1992) Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose escalation scheme. Eur J Cancer 28: 463-469
9. Fry DW, Boritzki TJ, Besserer JA, Jackson RC (1985) In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukaemia cells by a new class of DNA complexers, the anthra [1,9-cd] pyrazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol 34: 3499-3508
10. Gibaldi M (1991) Biopharmaceutics and clinical pharmacokinetics, 4th edn. Lea and Febiger, Philadelphia, pp 176-186
11. Graham MA, Newell DR, Butler J, Hoey B, Patterson LH (1987) The effect of the anthrapyrazole antitumour agent CI-941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes: inhibition of doxorubicin activation in vitro. Biochem Pharmacol 36: 3345-3351
12. Graham MA, Newell DR, Foster BJ, Calvert AH (1989) The pharmacokinetics and toxicity of the anthrapyrazole anticancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. Cancer Chemother Pharmacol 23: 8-14
13. Graham MA, Newell DR, Calvert AH (1989) Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid phase extraction and high performance liquid chromatography. J Chromatogr Biomed Appl 491: 253-261
14. Graham MA, Newell DR, Foster BJ, Gumbrell LA, Jenns KB, Calvert AH (1992) The clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the application of a pharmacokinetically guided dose escalation scheme. Cancer Res 52: 603-609
15. Ingram D, Block R (eds) (1984) Mathematical methods in medicine, part 1. Statistical and analytical techniques John Wiley and Sons, Chichester
16. Joel SP, Dolega-Ossowski H, Jones K, Clark PI, Johnson P, Slevin ML (1991) The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Am Assoc Cancer Res 32: 178
17. Launay MC, Milano G, Iliadis A, Frenay M, Namer N (1989) A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients. Br J Cancer 60: 89-92
18. Leopold WR, Nelson JM, Plowman J, Jackson RC (1985) Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine timours. Cancer Res 45: 5532-5539
19. Myers CE, McGuire WP, Liss RH, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science 197: 165-167
20. Ratain MJ, Vogelzang NJ (1987) Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 71: 935-939
21. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L (1989) Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48: 4127-4130
22. Scher HJ, Jodrell DI, Iverson J, Curley I, Egorin MJ, Tong W, Forrest A (1992) The use of adaptive control wilh feedback to individualize suramin dosing. Cancer Res 52: 64-70
23. Sorensen RT, Stromgren A, Jacobsen P, Jacobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324-327
24. Showalter HDH, Fry DW, Leopold WR, Lown JW, Plambeck JA, Reszka K (1986) Design, biochemical pharmacology, electrochemistry and antitumour biology of antitumor anthrapyrazoles. Anticancer Drug Design 1: 73-85
25. Showalter HDH, Johnson JL, Hoftiezer JM, Turner WR, Werbel LM, Leopold WR, Shillis JL, Elslager EF (1987) Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine tumours. J Med Chem 30: 121-131
26. Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the non-linear mixed-effect model. Drug Metab Rev 15: 265-292
27. Talbot DC, Smith IE, Mansi JL, Judson IR, Calvert AH, Ashley SE (1991) Anthrapyrazole CI-941: a highly active new agent in the treatment of advanced breast cancer. J Clin Oncol 9: 2141-2147
28. Yuen GJ, Drusano GL, Forrest A, Plaisance K, Caplan ES (1989) Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 46: 451-457